After hours:
Chart Events
Performance Outlook
| Previous Close | 45.74 |
| Open | 45.97 |
| Bid | 43.85 x 900 |
| Ask | 46.55 x 900 |
| Day's Range | 45.70 - 46.08 |
| 52 Week Range | 40.38 - 51.18 |
| Volume | |
| Avg. Volume | 666,883 |
| Market Cap | 10.456B |
| Beta (5Y Monthly) | 0.38 |
| PE Ratio (TTM) | 30.01 |
| EPS (TTM) | 1.53 |
| Earnings Date | Apr 24, 2023 - Apr 28, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 53.90 |
- GlobeNewswire
QIAGEN’s QIAxcel Connect wins Red Dot design award
International design competition recognizes high-resolution DNA or RNA capillary electrophoresis instrument // QIAxcel marks the fourth QIAGEN instrument to receive Red Dot award, highlights strategy of upgrading portfolio to add new features – in particular wireless connectivity // QIAxcel Connect offers scientists many benefits for nucleic acid analysis with minimal handling time, flexible throughput and speedVenlo, the Netherlands, March 29, 2023 (GLOBE NEWSWIRE) -- QIAGEN today announced tha
- Simply Wall St.
With 83% ownership, Qiagen N.V. (NYSE:QGEN) boasts of strong institutional backing
Key Insights Significantly high institutional ownership implies Qiagen's stock price is sensitive to their trading...
- Zacks
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of 8.33% and 2.86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
